Covid-19

Estudo randomizado | Vacina BCG não é efetiva em reduzir o absenteísmo de trabalhadores da atenção à saúde na pandemia de COVID-19.

2 Mai, 2022 | 14:01h

BCG vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial – Clinical Microbiology and Infection

 

Comentário no Twitter

BCG-CORONA RCT💥 @CMIJournal @MarcBonten
BCG-vaccination of health care worker exposed to #COVID19 patients did NOT reduce unplanned absenteeism nor documented COVID-19 #IDTwitter #MedEd #TwitteRx #MedTwitter https://t.co/yqnpmuy5Y8

— Antibiotic Steward Bassam Ghanem🆔🔥 (@ABsteward) April 28, 2022

 

---

M-A | Taxas de ataque secundário domiciliar de SARS-CoV-2 por variantes e status vacinal.

2 Mai, 2022 | 13:58h

Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis – JAMA Network Open

 

Comentário no Twitter

This systematic review & meta-analysis found household #SARSCoV2 secondary attack rates increased over time and were higher for variants than prior reported estimates. Vaccination was associated with reduced transmission (more for Alpha vs Delta & Omicron) https://t.co/6vwW0u3vY7

— JAMA Network Open (@JAMANetworkOpen) April 28, 2022

 

---

Covid-19: qual é a evidência para o uso do antiviral Paxlovid?

29 Abr, 2022 | 15:16h

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Conteúdos relacionados:

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

---

Análise Rasch | Desenvolvimento e validação do questionário de impacto dos sintomas para Covid longa (symptom burden questionnaire for long covid – SBQ-LC).

29 Abr, 2022 | 15:15h

Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis – The BMJ

 

Comentário no Twitter

New research developed and validated a symptom burden questionnaire for long covid which has the potential to benefit international clinical trials and inform clinical management https://t.co/akrRleap0W

— The BMJ (@bmj_latest) April 27, 2022

 

---

Estudo observacional | Impacto das vacinas contra Covid-19 na saúde pública dos EUA.

29 Abr, 2022 | 15:13h

Public health impact of covid-19 vaccines in the US: observational study – The BMJ

Editorial: The benefits of large scale covid-19 vaccination – The BMJ

 

Comentário no Twitter (fio – clique para saber mais)

Paper and accompanying editorial https://t.co/uwqY0PqYsE
"Many more lives could have been saved……
this new study is another confidence booster for covid-19 vaccines." pic.twitter.com/o4FygrAX8T

— Eric Topol (@EricTopol) April 27, 2022

 

---

Especialistas temem que os EUA padronizem o reforço anual de vacinas contra Covid sem dados suficientes.

29 Abr, 2022 | 15:11h

Experts fear U.S. may default to annual Covid boosters without sufficient data – STAT

 

Comentário no Twitter

Vaccine experts are concerned the U.S. may be sleepwalking into a policy of recommending annual Covid-19 vaccine boosters — without having generated the evidence to show they are actually needed. https://t.co/3TiNZvP0HY

— STAT (@statnews) April 26, 2022

 

---

Revisão clínica | Diagnóstico e tratamento da Covid-19 na gestação.

28 Abr, 2022 | 12:15h

Diagnosis and management of covid-19 in pregnancy – The BMJ

---

Estudo de coorte | Incidência da síndrome de Guillain-Barré após vacinação contra Covid-19.

28 Abr, 2022 | 12:07h

Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink – JAMA Network Open

 

Comentário no Twitter

This cohort study of #COVID19 vaccine safety surveillance in the US Vaccine Safety Datalink found a small elevated risk of Guillain-Barré syndrome after Janssen/J&J vaccine but not after mRNA COVID-19 vaccines. @KPDOR https://t.co/TTya5BDqeV

— JAMA Network Open (@JAMANetworkOpen) April 26, 2022

 

---

Sintomas persistentes de COVID-19 em estudo comunitário de 606.434 pessoas na Inglaterra.

27 Abr, 2022 | 16:41h

Persistent COVID-19 symptoms in a community study of 606,434 people in England – Nature Communications

 

Comentário no Twitter

Thirty-eight percent of participants from a community-based study of symptoms following COVID-19 reported persistent symptoms that lasted 12 weeks or more, according to an article published in @NatureComms. https://t.co/sAEutdOkSS pic.twitter.com/oCyyXGIRbk

— Nature Portfolio (@NaturePortfolio) April 20, 2022

 

---

Covid-19: estudo mostra que somente 1/4 dos pacientes admitidos em hospital sentem-se completamente recuperados após 1 ano.

27 Abr, 2022 | 16:39h

Covid-19: Only a quarter of patients admitted to hospital feel fully recovered after a year, study finds – The BMJ

Estudo original: Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study – The Lancet Respiratory Medicine

Comentário convidado: Long COVID: systemic inflammation and obesity as therapeutic targets – The Lancet Respiratory Medicine

 

Comentário no Twitter (fio – clique para saber mais)

PHOSP-COVID study:
– 232 (29%) of 804 pts fully recovered at 1y
– Female sex, obesity, & IMV = less likely to feel fully recovered
– inflamm mediators📈in those w/ most severe physical, mental health, & cognitive impairments

Read it here: https://t.co/rVZuVDo4xl

— The Lancet Respiratory Medicine (@LancetRespirMed) April 25, 2022

 

---